Bisegliptin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00525330)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
Dipeptidyl peptidase IV inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)C12CCC(NCC(=O)N3C[C@@H](F)C[C@H]3C#N)(CC1)CC2- Mol. weight
- 351.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297624 ↗
Also known as
- krp-104
- krp-104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00995345 | Phase 2 | Oct 1, 2009 | ActivX Biosciences, Inc., Kyorin Pharma |
| NCT00525330 | Phase 2 | Sep 1, 2007 | ActivX Biosciences, Inc., Kyorin Pharma, Medpace, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ActivX Biosciences, Inc. | For profit | 2 | 2 | 1 | 2007 |
| Kyorin Pharma | For profit | 2 | 0 | 1 | 2007 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1